Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
CCND1 and CDKN1A	cyclin D1	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	Chromatin organization Signaling by NOTCH Ubiquitin-dependent degradation of Cyclin D G1 Phase S Phase Cell Cycle, Mitotic RMTs methylate histone arginines Ubiquitin-dependent degradation of Cyclin D1 Cyclin D associated events in G1 Chromatin modifying enzymes Pre-NOTCH Transcription and Translation Pre-NOTCH Expression and Processing Mitotic G1-G1/S phases	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints	Arsenic trioxide
BRCA1 and MYC	breast cancer 1, early onset	v-myc avian myelocytomatosis viral oncogene homolog	ATM mediated phosphorylation of repair proteins Meiotic recombination Fanconi Anemia pathway ATM mediated response to DNA double-strand break Homologous Recombination Repair Meiotic synapsis Homologous recombination repair of replication-independent double-strand breaks Recruitment of repair and signaling proteins to double-strand breaks Double-Strand Break Repair	Loss of Function of TGFBR2 in Cancer Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Signaling by Wnt Cyclin E associated events during G1/S transition binding of TCF/LEF:CTNNB1 to target gene promoters TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway RNF mutants show enhanced WNT signaling and proliferation G1/S Transition Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Mitotic G1-G1/S phases FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer S Phase Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex TCF dependent signaling in response to WNT Signaling by NOTCH1 PEST Domain Mutants in Cancer Cyclin A:Cdk2-associated events at S phase entry Signaling by WNT in cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer
BRCA1 and BRCA2	breast cancer 1, early onset	breast cancer 2, early onset	ATM mediated phosphorylation of repair proteins Meiotic recombination Fanconi Anemia pathway ATM mediated response to DNA double-strand break Homologous Recombination Repair Meiotic synapsis Homologous recombination repair of replication-independent double-strand breaks Recruitment of repair and signaling proteins to double-strand breaks Double-Strand Break Repair	Homologous DNA pairing and strand exchange Meiotic recombination Fanconi Anemia pathway Homologous Recombination Repair Homologous recombination repair of replication-independent double-strand breaks Double-Strand Break Repair Presynaptic phase of homologous DNA pairing and strand exchange
BRCA2 and CCNE1	breast cancer 2, early onset	cyclin E1	Homologous DNA pairing and strand exchange Meiotic recombination Fanconi Anemia pathway Homologous Recombination Repair Homologous recombination repair of replication-independent double-strand breaks Double-Strand Break Repair Presynaptic phase of homologous DNA pairing and strand exchange	E2F mediated regulation of DNA replication DNA Damage/Telomere Stress Induced Senescence Cellular Senescence Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes p53-Dependent G1/S DNA damage checkpoint G0 and Early G1 S Phase Cyclin E associated events during G1/S transition Cell Cycle, Mitotic p53-Dependent G1 DNA Damage Response SCF(Skp2)-mediated degradation of p27/p21 G1/S Transition G1/S-Specific Transcription Cell Cycle Checkpoints Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Mitotic G1-G1/S phases G1/S DNA Damage Checkpoints
CCND2 and CDKN1A	cyclin D2	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	Cyclin D associated events in G1 G1 Phase Mitotic G1-G1/S phases Cell Cycle, Mitotic	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints
CCNE1 and CDKN1A	cyclin E1	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	E2F mediated regulation of DNA replication DNA Damage/Telomere Stress Induced Senescence Cellular Senescence Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes p53-Dependent G1/S DNA damage checkpoint G0 and Early G1 S Phase Cyclin E associated events during G1/S transition Cell Cycle, Mitotic p53-Dependent G1 DNA Damage Response SCF(Skp2)-mediated degradation of p27/p21 G1/S Transition G1/S-Specific Transcription Cell Cycle Checkpoints Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Mitotic G1-G1/S phases G1/S DNA Damage Checkpoints	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints
CDKN2A and MYC	cyclin-dependent kinase inhibitor 2A	v-myc avian myelocytomatosis viral oncogene homolog	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic Oxidative Stress Induced Senescence Cellular Senescence Oncogene Induced Senescence	Loss of Function of TGFBR2 in Cancer Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Signaling by Wnt Cyclin E associated events during G1/S transition binding of TCF/LEF:CTNNB1 to target gene promoters TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway RNF mutants show enhanced WNT signaling and proliferation G1/S Transition Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Mitotic G1-G1/S phases FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer S Phase Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex TCF dependent signaling in response to WNT Signaling by NOTCH1 PEST Domain Mutants in Cancer Cyclin A:Cdk2-associated events at S phase entry Signaling by WNT in cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer
CTNNB1 and TGFBR2	catenin (cadherin-associated protein), beta 1, 88kDa	transforming growth factor, beta receptor II (70/80kDa)	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer	Urea	Glycerol
SMAD2 and MYC	SMAD family member 2	v-myc avian myelocytomatosis viral oncogene homolog	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer	Loss of Function of TGFBR2 in Cancer Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Signaling by Wnt Cyclin E associated events during G1/S transition binding of TCF/LEF:CTNNB1 to target gene promoters TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway RNF mutants show enhanced WNT signaling and proliferation G1/S Transition Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Mitotic G1-G1/S phases FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer S Phase Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex TCF dependent signaling in response to WNT Signaling by NOTCH1 PEST Domain Mutants in Cancer Cyclin A:Cdk2-associated events at S phase entry Signaling by WNT in cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer
SMAD4 and TGFBR2	SMAD family member 4	transforming growth factor, beta receptor II (70/80kDa)	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by BMP Transcriptional regulation of pluripotent stem cells Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer		Glycerol
SMAD7 and TGFBR2	SMAD family member 7	transforming growth factor, beta receptor II (70/80kDa)	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling Loss of Function of SMAD4 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Signaling by BMP Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Loss of Function of TGFBR1 in Cancer Generic Transcription Pathway Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer SMAD4 MH2 Domain Mutants in Cancer	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer		Glycerol
TERT and TGFBR2	telomerase reverse transcriptase	transforming growth factor, beta receptor II (70/80kDa)	Telomere Maintenance Chromosome Maintenance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation formation of the beta-catenin:TCF transactivating complex Extension of Telomeres Telomere Extension By Telomerase XAV939 inhibits tankyrase, stabilizing AXIN Signaling by Wnt Signaling by WNT in cancer	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer		Glycerol
PARP1 and CDKN1A	poly (ADP-ribose) polymerase 1	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity TGFBR1 LBD Mutants in Cancer Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Loss of Function of TGFBR1 in Cancer Generic Transcription Pathway Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer SMAD4 MH2 Domain Mutants in Cancer	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints	Carba-Nicotinamide-Adenine-Dinucleotide NU1025 Nicotinamide 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone 3-Methoxybenzamide 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide 3,4-Dihydro-5-Methyl-Isoquinolinone 2-(3\'-Methoxyphenyl) Benzimidazole-4-Carboxamide 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
AP2B1 and TGFBR2	adaptor-related protein complex 2, beta 1 subunit	transforming growth factor, beta receptor II (70/80kDa)	Retrograde neurotrophin signalling Axon guidance HIV Infection Nef Mediated CD8 Down-regulation L1CAM interactions Signaling by Wnt Signaling by EGFRvIII in Cancer Recycling pathway of L1 EPH-ephrin mediated repulsion of cells MHC class II antigen presentation EPH-Ephrin signaling Nef Mediated CD4 Down-regulation EGFR downregulation Signalling by NGF Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters Host Interactions of HIV factors The role of Nef in HIV-1 replication and disease pathogenesis Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer beta-catenin independent WNT signaling Signaling by EGFR WNT5A-dependent internalization of FZD4 Signaling by EGFR in Cancer PCP/CE pathway Adaptive Immune System	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer		Glycerol
AKT1 and CDKN1A	v-akt murine thymoma viral oncogene homolog 1	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Activation of BH3-only proteins Signaling by Wnt Platelet Aggregation (Plug Formation) Signaling by EGFRvIII in Cancer AKT phosphorylates targets in the cytosol Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Regulation of beta-cell development PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling DAP12 interactions Regulation of mRNA stability by proteins that bind AU-rich elements GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 Activation of BAD and translocation to mitochondria Signaling by EGFR GPCR downstream signaling Signaling by VEGF AKT phosphorylates targets in the nucleus Downstream signal transduction Regulation of gene expression in beta cells Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Adaptive Immune System Costimulation by the CD28 family PIP3 activates AKT signaling Translocation of GLUT4 to the plasma membrane deactivation of the beta-catenin transactivating complex VEGFA-VEGFR2 Pathway Metabolism of nitric oxide G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling VEGFR2 mediated vascular permeability Downstream signaling of activated FGFR Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN eNOS activation and regulation Intrinsic Pathway for Apoptosis Butyrate Response Factor 1 (BRF1) destabilizes mRNA Innate Immune System Signalling by NGF CTLA4 inhibitory signaling AKT-mediated inactivation of FOXO1A Integrin alphaIIb beta3 signaling Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Negative regulation of the PI3K/AKT network Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR eNOS activation TCF dependent signaling in response to WNT KSRP destabilizes mRNA GPVI-mediated activation cascade Signaling by WNT in cancer	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints	Adenosine triphosphate Arsenic trioxide Inositol 1,3,4,5-Tetrakisphosphate N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
APC and AXIN2	adenomatous polyposis coli	axin 2	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation formation of the beta-catenin:TCF transactivating complex XAV939 inhibits tankyrase, stabilizing AXIN degradation of AXIN Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters Signaling by WNT in cancer
APC and CSNK1A1	adenomatous polyposis coli	casein kinase 1, alpha 1	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Hedgehog 'off' state misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated Hedgehog 'on' state XAV939 inhibits tankyrase, stabilizing AXIN Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by Hedgehog Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Degradation of GLI2 by the proteasome Activation of SMO
APC and CTNNB1	adenomatous polyposis coli	catenin (cadherin-associated protein), beta 1, 88kDa	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer		Urea
AR and DCC	androgen receptor	DCC netrin 1 receptor	Generic Transcription Pathway Nuclear Receptor transcription pathway	DSCAM interactions Axon guidance Role of second messengers in netrin-1 signaling DCC mediated attractive signaling Programmed Cell Death Netrin mediated repulsion signals Netrin-1 signaling Role of DCC in regulating apoptosis Extrinsic Pathway	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and PTEN	androgen receptor	phosphatase and tensin homolog	Generic Transcription Pathway Nuclear Receptor transcription pathway	Signaling by the B Cell Receptor (BCR) Downstream TCR signaling Metabolism of lipids and lipoproteins Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Synthesis of PIPs at the plasma membrane Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation Synthesis of IP3 and IP4 in the cytosol PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Phospholipid metabolism PI Metabolism Innate Immune System Signaling by PDGF DAP12 interactions Signalling by NGF GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Negative regulation of the PI3K/AKT network Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Inositol phosphate metabolism PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR TCR signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide

Search Results for: Cancer